Bhangare Dhiraj, Rajput Niraj, Jadav Tarang, Sahu Amit Kumar, Sengupta Pinaki
Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), Gandhinagar, India.
Rapid Commun Mass Spectrom. 2023 Jan 15;37(1):e9417. doi: 10.1002/rcm.9417.
Capmatinib (CMT) has been recently approved for the treatment of non-small cell lung cancer by the United States Food and Drug Administration (USFDA). Till date, the degradation mechanism of CMT in different stress conditions is not known. Moreover, degradation products (DPs) of the drug are yet to be identified. Characterization study on degradation products of CMT has not been reported before. Furthermore, no previously reported literature is available on the stability-indicating method of CMT.
Owing to the lack of such scientific reports, we developed a sensitive, stability-indicating method for CMT which can resolve it from all its degradation products. The method was validated as per the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH Q2 [R1]) guideline. We studied and established the degradation mechanism of CMT in different stress conditions. One degradation product (DP2) was isolated and characterized using H NMR.
The degradation products (DP1, DP2 and DP3) of the drug have been identified and characterized for the first time by using high-resolution mass spectrometry and H NMR spectroscopy. CMT was found to become degraded under acidic, basic and photolytic stress conditions in the solution phase to yield three major DPs. The drug was found to be stable in neutral hydrolysis, oxidation and thermal stress conditions.
DP1 was formed under acidic and basic hydrolytic conditions, whereas DP2 and DP3 were formed under photolytic conditions. Characterization of all the DPs has been carried out to establish their structures and understand the molecular mechanism behind the degradation of the drug. Few studies reported quantitative analysis of CMT and its metabolites in biological fluids. However, this is the first study to identify the unknown DPs of CMT and the mechanism of its degradation. Moreover, this article reports a stability-indicating analytical method for CMT which has not yet been reported in any literature.
卡马替尼(CMT)最近已被美国食品药品监督管理局(USFDA)批准用于治疗非小细胞肺癌。迄今为止,CMT在不同应激条件下的降解机制尚不清楚。此外,该药物的降解产物(DPs)尚未被鉴定。此前尚未有关于CMT降解产物的表征研究报道。此外,也没有关于CMT稳定性指示方法的先前报道文献。
由于缺乏此类科学报告,我们开发了一种灵敏的CMT稳定性指示方法,该方法能够将其与所有降解产物分离。该方法按照国际人用药品注册技术协调会(ICH Q2 [R1])指南进行了验证。我们研究并确定了CMT在不同应激条件下的降解机制。使用1H NMR分离并表征了一种降解产物(DP2)。
首次使用高分辨率质谱和1H NMR光谱对该药物的降解产物(DP1、DP2和DP3)进行了鉴定和表征。发现CMT在溶液相中于酸性、碱性和光解应激条件下会降解,产生三种主要的DPs。发现该药物在中性水解、氧化和热应激条件下是稳定的。
DP1在酸性和碱性水解条件下形成,而DP2和DP3在光解条件下形成。已对所有DPs进行了表征,以确定其结构并了解药物降解背后的分子机制。很少有研究报道生物流体中CMT及其代谢物的定量分析。然而,这是第一项鉴定CMT未知DPs及其降解机制的研究。此外,本文报道了一种CMT的稳定性指示分析方法,此前尚无任何文献报道。